NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT

Information

  • Research Project
  • 8097160
  • ApplicationId
    8097160
  • Core Project Number
    U10CA012027
  • Full Project Number
    3U10CA012027-40S1
  • Serial Number
    12027
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/2/2010 - 14 years ago
  • Project End Date
    6/30/2011 - 13 years ago
  • Program Officer Name
    MOONEY, MARGARET M
  • Budget Start Date
    7/2/2010 - 14 years ago
  • Budget End Date
    6/30/2011 - 13 years ago
  • Fiscal Year
    2010
  • Support Year
    40
  • Suffix
    S1
  • Award Notice Date
    7/2/2010 - 14 years ago
Organizations

NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT

The American Cancer Society estimated that in 2004, breast or colorectal cancer would strike over 350,000 Americans and close to 100,000 people would die from these diseases. The National Surgical Adjuvant Breast and Bowel Project(NSABP) is a multi-center clinical cooperative trials group with nearly 200 member institutions located throughout the US, Canada and Puerto Rico. The primary research objective of the NSABP is to conduct therapeutic research designed to improve the survival and the quality of life for persons with breast or colorectal cancer. This goal is achieved through the conduct of definitive phase III trials and the developmental efforts that lead to them. In calendar years 2002 and 2003, the NSABP entered 10,270 breast cancer patients and 962 colorectal cancer patients into adjuvant therapy trials. According to NCI data, this represents 64% of the breast cancer patients and 78% of the colorectal cancer patients entering NCI sponsored phase III cooperative group adjuvant breast or colorectal adjuvant trials. The NSABP integrates key behavior and health outcomes into its phase III trials to provide added value to the traditional endpoints of disease-free and overall survival. The NSABP also conducts correlative laboratory research in conjunction with its clinical trials designed to improve methods of assessing prognosis and predicting response to treatment with the aim of optimizing therapy for individual patients. In the proposed project period our aim will be to continue to improve breast and colorectal cancer therapies through the development and conduct of well-designed Phase III adjuvant therapy trials which will be carried out at our extensive network of affiliated members throughout North America.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    U10
  • Administering IC
    CA
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    188932
  • Sub Project Total Cost
  • ARRA Funded
    True
  • CFDA Code
    701
  • Ed Inst. Type
  • Funding ICs
    NCI:188932\
  • Funding Mechanism
    Other Research Related
  • Study Section
    NCI
  • Study Section Name
    Subcommittee B - Comprehensiveness
  • Organization Name
    NSABP FOUNDATION, INC.
  • Organization Department
  • Organization DUNS
    107186988
  • Organization City
    PITTSBURGH
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    152125256
  • Organization District
    UNITED STATES